Where is scientific evidence supporting EU policy on BSE and pharmaceuticals?BMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7131.629 (Published 14 February 1998) Cite this as: BMJ 1998;316:629
- Alan Earl-Slater, Senior lecturer in health economics
- Department of Medicines Management, Keele University, Keele, Staffordshire ST5 5BG
EDITOR—Bowser is right to attempt to provide an update of European Union (EU) policies regarding bovine spongiform encephalopathy and pharmaceuticals.1 Unfortunately his letter misses the main concern of my earlier letter2: where is the evidence supporting any of the EU's policies on bovine spongiform encephalopathy and pharmaceuticals?
Bowser is wrong to state that amendments to the EU directive on spongiform encephalopathy will not affect drugs. The commission's decision of 30 July (not 29 July as he stated) …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial